amiodarone has been researched along with Critical Illness in 20 studies
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.
Critical Illness: A disease or state in which death is possible or imminent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Amiodarone is a highly effective antiarrhythmic agent for the treatment and prevention of atrial and ventricular arrhythmias." | 8.12 | Liver failure caused by intravenous amiodarone and effective intervention measures: A case report. ( Jiang, Z; Li, X; Yan, R; Yi, W; Zhao, C, 2022) |
| " Amiodarone, an antiarrhythmic associated with significant adverse effects with long-term use, is commonly used for new-onset atrial fibrillation in critical illness (NAFCI)." | 7.85 | Evaluation of Deprescribing Amiodarone After New-Onset Atrial Fibrillation in Critical Illness. ( Alpert, J; Bloom, J; Dongtai, W; Huckleberry, Y; Kopp, B; Leelathanalerk, A, 2017) |
| "Amiodarone is the gold-standard medication to control heart rate in critically ill patients with atrial tachyarrhythmias (ATs); however, effective doses and covariates influencing its efficacy remain unknown." | 7.83 | Modeling of Amiodarone Effect on Heart Rate Control in Critically Ill Patients with Atrial Tachyarrhythmias. ( Aissaoui, N; Alazard, M; El-Aissaoui, M; Faisy, C; Funck-Brentano, C; Hulot, JS; Le-Heuzey, JY; Salem, JE; Urien, S, 2016) |
| "Amiodarone should be administered as a bolus dose followed immediately with an infusion when treating atrial fibrillation in the medical-surgical intensive care unit." | 7.83 | Variable use of amiodarone is associated with a greater risk of recurrence of atrial fibrillation in the critically ill. ( Bandeshe, H; Boots, R; Clement, P; Mitrić, G; Udy, A, 2016) |
| "A retrospective review was done to determine the efficacy and hemodynamic effects of slow intravenous amiodarone administration on invasively monitored patients with acute onset of atrial fibrillation or atrial flutter and left ventricular ejection fractions < 15%." | 7.69 | Intravenous amiodarone for therapy of atrial fibrillation and flutter in critically ill patients with severely depressed left ventricular function. ( Kumar, A, 1996) |
| "Amiodarone dose was associated to HR decrease but not to MAP or plasma lactate increase." | 5.46 | Effectiveness of heart rate control on hemodynamics in critically ill patients with atrial tachyarrhythmias managed by amiodarone. ( Aissaoui, N; Dureau, P; El-Aissaoui, M; Faisy, C; Funck-Brentano, C; Hulot, JS; Salem, JE; Urien, S, 2017) |
| "Amiodarone is widely used in intensive care units for the treatment of a variety of arrhythmias." | 4.80 | Intravenous amiodarone in intensive care. Time for a reappraisal? ( Binning, A; Hughes, M, 2000) |
| "Amiodarone is a highly effective antiarrhythmic agent for the treatment and prevention of atrial and ventricular arrhythmias." | 4.12 | Liver failure caused by intravenous amiodarone and effective intervention measures: A case report. ( Jiang, Z; Li, X; Yan, R; Yi, W; Zhao, C, 2022) |
| "Providing IV and PO overlap of amiodarone for a median of 4 hours did not decrease the rate of early tachyarrhythmia recurrence." | 3.91 | Clinical effects of intravenous to oral amiodarone transition strategies in critically ill adult patients. ( Aberle, C; Altshuler, D; Arnouk, S; Merchan, C; Papadopoulos, J; Piper, GL, 2019) |
| " Amiodarone, an antiarrhythmic associated with significant adverse effects with long-term use, is commonly used for new-onset atrial fibrillation in critical illness (NAFCI)." | 3.85 | Evaluation of Deprescribing Amiodarone After New-Onset Atrial Fibrillation in Critical Illness. ( Alpert, J; Bloom, J; Dongtai, W; Huckleberry, Y; Kopp, B; Leelathanalerk, A, 2017) |
| "Amiodarone is the gold-standard medication to control heart rate in critically ill patients with atrial tachyarrhythmias (ATs); however, effective doses and covariates influencing its efficacy remain unknown." | 3.83 | Modeling of Amiodarone Effect on Heart Rate Control in Critically Ill Patients with Atrial Tachyarrhythmias. ( Aissaoui, N; Alazard, M; El-Aissaoui, M; Faisy, C; Funck-Brentano, C; Hulot, JS; Le-Heuzey, JY; Salem, JE; Urien, S, 2016) |
| "Amiodarone should be administered as a bolus dose followed immediately with an infusion when treating atrial fibrillation in the medical-surgical intensive care unit." | 3.83 | Variable use of amiodarone is associated with a greater risk of recurrence of atrial fibrillation in the critically ill. ( Bandeshe, H; Boots, R; Clement, P; Mitrić, G; Udy, A, 2016) |
| "A retrospective review was done to determine the efficacy and hemodynamic effects of slow intravenous amiodarone administration on invasively monitored patients with acute onset of atrial fibrillation or atrial flutter and left ventricular ejection fractions < 15%." | 3.69 | Intravenous amiodarone for therapy of atrial fibrillation and flutter in critically ill patients with severely depressed left ventricular function. ( Kumar, A, 1996) |
| "Amiodarone was the most commonly studied agent (10 studies), followed by beta-blockers (8), calcium channel blockers (6) and magnesium (3)." | 2.66 | Managing new-onset atrial fibrillation in critically ill patients: a systematic narrative review. ( Bedford, J; O'Bryan, LJ; Petrinic, T; Redfern, OC; Watkinson, PJ; Young, JD, 2020) |
| "Amiodarone dose was associated to HR decrease but not to MAP or plasma lactate increase." | 1.46 | Effectiveness of heart rate control on hemodynamics in critically ill patients with atrial tachyarrhythmias managed by amiodarone. ( Aissaoui, N; Dureau, P; El-Aissaoui, M; Faisy, C; Funck-Brentano, C; Hulot, JS; Salem, JE; Urien, S, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (15.00) | 18.2507 |
| 2000's | 3 (15.00) | 29.6817 |
| 2010's | 10 (50.00) | 24.3611 |
| 2020's | 4 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gillmann, HJ | 1 |
| Busche, P | 1 |
| Leffler, A | 1 |
| Stueber, T | 1 |
| Jiang, Z | 1 |
| Zhao, C | 1 |
| Li, X | 1 |
| Yi, W | 1 |
| Yan, R | 1 |
| O'Bryan, LJ | 1 |
| Redfern, OC | 1 |
| Bedford, J | 1 |
| Petrinic, T | 1 |
| Young, JD | 1 |
| Watkinson, PJ | 1 |
| Bosch, NA | 1 |
| Rucci, JM | 1 |
| Massaro, JM | 1 |
| Winter, MR | 1 |
| Quinn, EK | 1 |
| Chon, KH | 1 |
| McManus, DD | 1 |
| Walkey, AJ | 1 |
| Leelathanalerk, A | 1 |
| Dongtai, W | 1 |
| Huckleberry, Y | 1 |
| Kopp, B | 1 |
| Bloom, J | 1 |
| Alpert, J | 1 |
| Salem, JE | 2 |
| Dureau, P | 1 |
| Funck-Brentano, C | 2 |
| Hulot, JS | 2 |
| El-Aissaoui, M | 2 |
| Aissaoui, N | 2 |
| Urien, S | 2 |
| Faisy, C | 2 |
| Fernandes, FM | 1 |
| Silva, EP | 1 |
| Martins, RR | 1 |
| Oliveira, AG | 1 |
| Arnouk, S | 1 |
| Aberle, C | 1 |
| Altshuler, D | 1 |
| Merchan, C | 1 |
| Piper, GL | 1 |
| Papadopoulos, J | 1 |
| Alazard, M | 1 |
| Le-Heuzey, JY | 1 |
| Mitrić, G | 1 |
| Udy, A | 1 |
| Bandeshe, H | 1 |
| Clement, P | 1 |
| Boots, R | 1 |
| Su, M | 1 |
| Seki, D | 1 |
| Moheet, AM | 1 |
| Walton, J | 1 |
| Auer, J | 1 |
| Lamm, G | 1 |
| Willich, T | 1 |
| Hammwöhner, M | 1 |
| Goette, A | 1 |
| Santos, D | 1 |
| Carron, PN | 1 |
| Yersin, B | 1 |
| Pasquier, M | 1 |
| Kumar, A | 1 |
| Schuster, MM | 1 |
| Clemo, HF | 1 |
| Wood, MA | 1 |
| Gilligan, DM | 1 |
| Ellenbogen, KA | 1 |
| Hughes, M | 1 |
| Binning, A | 1 |
| Delle Karth, G | 1 |
| Geppert, A | 1 |
| Neunteufl, T | 1 |
| Priglinger, U | 1 |
| Haumer, M | 1 |
| Gschwandtner, M | 1 |
| Siostrzonek, P | 1 |
| Heinz, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Modeling of Amiodarone Effect on Heart Rate Control in Critically Ill Patients With Atrial Tachyarrhythmias[NCT03413150] | 80 participants (Actual) | Observational | 2007-01-31 | Completed | |||
| Observational Study to Evaluate the Effects on the Qt Interval of COVID-19 Coronavirus Infection in Critically Ill Patients[NCT04422535] | 80 participants (Anticipated) | Observational | 2020-05-29 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for amiodarone and Critical Illness
| Article | Year |
|---|---|
Managing new-onset atrial fibrillation in critically ill patients: a systematic narrative review.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Atrial Fibrillation; Calcium Channel Blockers; Criti | 2020 |
[Therapy of atrial fibrillation in the critically ill].
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Comorbidity; Contraindicati | 2012 |
EZ-IO(®) intraosseous device implementation in a pre-hospital emergency service: A prospective study and review of the literature.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amiodarone; Analgesics; Anti-Arrhythmia Agents; Atropine | 2013 |
Intravenous amiodarone in intensive care. Time for a reappraisal?
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Critical Care; Critical Illness; Drug Inte | 2000 |
1 trial available for amiodarone and Critical Illness
| Article | Year |
|---|---|
Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias.
Topics: Aged; Amiodarone; Analysis of Variance; Anti-Arrhythmia Agents; APACHE; Atrial Fibrillation; Atrial | 2001 |
15 other studies available for amiodarone and Critical Illness
| Article | Year |
|---|---|
Effectiveness of amiodarone versus digitalis for heart rate control in critically ill patients with new-onset atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Critical Illness; | 2022 |
Liver failure caused by intravenous amiodarone and effective intervention measures: A case report.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Critical Illness; Humans; Infusions, | 2022 |
Comparative Effectiveness of Heart Rate Control Medications for the Treatment of Sepsis-Associated Atrial Fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2021 |
Evaluation of Deprescribing Amiodarone After New-Onset Atrial Fibrillation in Critical Illness.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiologists; Critical Illness; Depr | 2017 |
Effectiveness of heart rate control on hemodynamics in critically ill patients with atrial tachyarrhythmias managed by amiodarone.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Cohort Studies; Critical Illness; Femal | 2017 |
QTc interval prolongation in critically ill patients: Prevalence, risk factors and associated medications.
Topics: Adult; Aged; Amiodarone; Clopidogrel; Critical Illness; Cross-Sectional Studies; Electrocardiography | 2018 |
Clinical effects of intravenous to oral amiodarone transition strategies in critically ill adult patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillati | 2019 |
Modeling of Amiodarone Effect on Heart Rate Control in Critically Ill Patients with Atrial Tachyarrhythmias.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cohort Studies; Cr | 2016 |
Variable use of amiodarone is associated with a greater risk of recurrence of atrial fibrillation in the critically ill.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cohort Studies; Critical Illness; Fem | 2016 |
Pharmacologic cardioversion with intravenous amiodarone is likely safe in neurocritically Ill patients.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fib | 2017 |
The need for adequate rate control points to amiodarone as the drug of choice for treating critically ill patients with acute onset atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Critical Illness; Humans | 2008 |
Drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction: What does the crystal ball tell you?
Topics: Amiodarone; Anti-Arrhythmia Agents; Critical Care; Critical Illness; Electrocardiography; Female; Hu | 2011 |
Intravenous amiodarone for therapy of atrial fibrillation and flutter in critically ill patients with severely depressed left ventricular function.
Topics: Acute Disease; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Critic | 1996 |
Management of incessant ventricular tachycardia in a 39-year-old woman with cardiomyopathy.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathy, Dilated; Critical Illness; Defibrillators | 1997 |
Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias.
Topics: Aged; Amiodarone; Critical Illness; Female; Heart Rate; Humans; Infusions, Intravenous; Male; Middle | 1998 |